Rain oncology stock.

Which Rain Oncology insiders have been selling company stock? The following insider sold RAIN shares in the last 24 months: Boxer Capital, Llc ($1,243,750.00). How much insider selling is happening at Rain Oncology?Stock and Other Ownership Interests: Rain Oncology Consulting or Advisory Role: GreenPeptide, AstraZeneca, Roche/Genentech, Rain Oncology, Blueprint Medicines, Guardant Health Patents, Royalties, Other Intellectual Property: Licensing fees for patent from Rain Oncology, Licensing fees from Takeda for Biologic Materials, Licensing fees from ...Feb 23, 2023. NEWARK, Calif., Thursday, February 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the fourth ...Shares of precision oncology upstart Rain Oncology (NASDAQ:RAIN) have fallen by nearly 40% since its IPO was priced at $17 in 2021. Trailing twelve month gain is a more respectable +35%. Trailing ...

Oct 16, 2023. NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the …WebNEWARK, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the first quarter ...

4 Wall Street analysts have issued 1 year target prices for Pyxis Oncology's stock. Their PYXS share price targets range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 629.2% from the stock's current price.AI Stock 12 Months Forecast. Based on 10 Wall Street analysts offering 12 month price targets for C3ai in the last 3 months. The average price target is $25.00 with a high forecast of $42.00 and a low forecast of $14.00. The average price target represents a -9.42% change from the last price of $27.60.

Track Rain Therapeutics Inc (RAIN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsWebTSLA Stock 12 Months Forecast. $248.93. (11.27% Upside) Based on 34 Wall Street analysts offering 12 month price targets for Tesla in the last 3 months. The average price target is $248.93 with a high forecast of $380.00 and a low forecast of $85.00. The average price target represents a 11.27% change from the last price of $223.71.‍ Rain Oncology was founded in 2017 as a precision oncology company leveraging a deep scientific knowledge of drug mechanism and designing clinical trials with the most appropriate patient population most likely to benefit from treatment. Rain is focused on a few critical objectives: (1) strive to greatly enhance probabilities of therapeutic ...Check out other analyst stock ratings. H.C. Wainwright On Rain Oncology. Analyst Mitchell Kapoor downgraded the rating on the stock to Neutral. “Since LPS harbors the highest prevalence of MDM2 ...Quantum-Si cuts 12% of workers. Quantum-Si, a proteomics firm, said it would lay off roughly 12% of its workforce in the first quarter of 2023. The restructuring efforts will cost the company roughly $1 million. Since its 2021 merger with a special purpose acquisition company, Quantum-Si’s stock has struggled.

Track Rain Therapeutics Inc (RAIN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Jan 20, 2023 · PURPOSE This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers. PATIENTS AND METHODS In this first-in-human phase I study, patients with advanced solid tumors or lymphomas received milademetan orally once daily as extended/continuous (days 1-21 or 1 ...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Rain Oncology, Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or …NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...What is the target price for Rain Oncology (RAIN) stock? The latest price target for Rain Oncology ( NASDAQ: RAIN) was reported by Citigroup on Monday, September 18, 2023. The analyst firm set a ...31 May 2023 ... Rain plans to continue evaluating the Phase 3 MANTRA data and present those findings at a medical conference later in the year. The company also ...Stock analysis for Rain Oncology Inc (RAIN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.The Complete List of Biotech Stocks Trading on the NASDAQ as of Nov 29, 2023 are listed below: ... Cardiff Oncology Inc. CRDF: United States: 32: Curis Inc. CRIS: United States: 33: CRISPR Therapeutics AG : CRSP: ... Rain Oncology Inc. RAIN: United States: 601: RAPT Therapeutics Inc. RAPT: United States: 602:Rain Oncology. stock was originally listed at a price of $15.80 in Apr 23, 2021. If you had invested in Rain Oncology stock at $15.80, your return over the last 2 years would have been -93.23%, for an annualized return of -73.98% (not including any dividends or dividend reinvestments).

Rain Oncology Inc. (RAIN) Stock Price | Stock Quote Nasdaq - MarketScreener RAIN ONCOLOGY INC. Rain Oncology Inc. Stock price Equities …Rain Oncology stock plummets on late-stage cancer drug results - San Francisco Business Times bizjournals.com 1 Like Comment Share Copy; LinkedIn; Facebook; Twitter; To view ...Wafik El-Deiry, MD, PhD, FACP, Director of the Cancer Center at Brown University, will discuss the MDM2-p53 pathway . Mrinal Gounder, MD, Medical Oncologist at Memorial Sloan Kettering Cancer Center, will discuss the prior milademetan phase 1 data and background in patients with liposarcoma, and scientific rationale for the milademetan …WebView the latest Rain Oncology Inc. (RAIN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Description. Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology.

Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting …Web

Rain and other forms of precipitation occur when water accumulates in the clouds and falls to the ground. This occurs due to the water cycle, which continually recycles the water on Earth.NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds ...Shares of Cullinan Oncology ( CGEM 3.30%) were up as much as 24.3% this week after being as high as 24.9%, according to data provided by S&P Global Market Intelligence. The stock closed last week ...[relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of Rain Therapeutics Inc. (RAIN) Rain Therapeutics Inc. is a biotechnology company focused on targeted therapies for patients with cancer. The company was founded in 2017 and is headquartered in Newark, California. Since its inception, Rain Therapeutics has …POAI 15 min Scalpers edition test Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, Skyline, Soluble, and test Predictive …Rain Oncology Inc ( RAIN) is down -3.97%% today. RAIN has an Overall Score of 52. Find out what this means to you and get the rest of the rankings on RAIN! See Full RAIN Report. RAIN stock closed at $1.26 and is down -$0.05 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only ...Jan 20, 2023 · Stock and Other Ownership Interests: Rain Oncology Consulting or Advisory Role: GreenPeptide, AstraZeneca, Roche/Genentech, Rain Oncology, Blueprint Medicines, Guardant Health Patents, Royalties, Other Intellectual Property: Licensing fees for patent from Rain Oncology, Licensing fees from Takeda for Biologic Materials, Licensing fees from ... 0.82%. ARM. 3.90%. Get the latest Mural Oncology PLC (MURA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ...Stock Ward (E320) Zone E, 3rd floor - room 20 Plastic Surgery Ward Call 01245 513922. Visiting times are between 11am to 9pm . Stroke Unit (A302) ... Oncology, Haematology Ground Floor, Prittlewell Building. Call 01702 435555 ext 6255. Endoscopy Unit Mz, Tower Block. Call 01702 385096.

Stock Quote & Chart. Historical Price Lookup. ... Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR ...

In the previous week, Rain Oncology had 18 more articles in the media than Celularity. MarketBeat recorded 21 mentions for Rain Oncology and 3 mentions for Celularity. Rain Oncology's average media sentiment score of 0.63 beat Celularity's score of -0.07 indicating that Celularity is being referred to more favorably in the media.

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...Rain Oncology last announced its earnings data on November 9th, 2023. The reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. Rain Oncology has generated ($2.06) earnings per share over the last year (($2.06) diluted earnings per share).May 22, 2023. NEWARK, Calif., May 22, 2023 – Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and ...0.82%. ARM. 3.90%. Get the latest Mural Oncology PLC (MURA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ...[relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of Rain Therapeutics Inc. (RAIN) Rain Therapeutics Inc. is a biotechnology company focused on targeted therapies for patients with cancer. The company was founded in 2017 and is headquartered in Newark, California. Since its inception, Rain Therapeutics has …You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.On average, Wall Street analysts predict that Rain Oncology's share price could fall to $1.00 by Sep 18, 2024. The average Rain Oncology stock price prediction ...Stock Detail•Compare Perf. •Options Chain•Save to Portfolio•Create Alert Scroll to Statements Show Previous Ratings Rain Oncology, Inc. is a clinical-stage precision …1.0900. +0.0200. +1.87%. Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 ...WebPURPOSE This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers. PATIENTS AND METHODS In this first-in-human phase I study, patients with advanced solid tumors or lymphomas received milademetan orally once daily as extended/continuous (days 1-21 or 1 ...Nov 9, 2023 · As of November 3, 2023, Rain had approximately 36.4 million shares of common stock outstanding. About Rain Oncology Inc. Rain Oncology Inc. is a precision oncology company developing therapies ... Rain Therapeutics. NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology ...

Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer. We are on a journey to shut down one of cancer’s most commonly mutated signaling cascades, the RAS/MAPK pathway, which affects approximately 5.5 million lives each year worldwide. Our promising pipeline targets the RAS/MAPK pathway at virtually every turn, …POAI 15 min Scalpers edition test Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, Skyline, Soluble, and test Predictive …Exhibit 10.15 FIRST AMENDMENT TO. RAIN THERAPEUTICS INC. 2021. EMPLOYEE STOCK PURCHASE PLAN. WHEREAS, Rain Oncology Inc. (f/k/a Rain Therapeutics Inc.), a Delaware corporation (the “Company”) maintains the Rain Therapeutics Inc. 2021 Employee Stock Purchase Plan (the “Plan”); . WHEREAS, …With Rain Oncology stock trading at $1.07 per share, the total value of Rain Oncology stock (market capitalization) is $38.92M.Rain Oncology. stock was originally listed at a price of $15.80 in Apr 23, 2021. If you had invested in Rain Oncology stock at $15.80, your return over the last 2 years would have been -93.23%, for an …WebInstagram:https://instagram. tsla german stock marketbkun m gcostco vending machines for saledaytrading for dummiesemini broker The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.Complete Rain Oncology Inc. stock information by Barron's. View real-time RAIN stock price and news, along with industry-best analysis. monthly dividend etf list 7 brokerages have issued 1 year price targets for ALX Oncology's stock. Their ALXO share price targets range from $10.00 to $34.00. On average, they anticipate the company's stock price to reach $20.42 in the next year. This suggests a possible upside of 154.9% from the stock's current price. View analysts price targets for ALXO or view …“As a surgical oncologist, I have worked to reduce racial, ethnic and gender health care disparities throughout my career. Tempus is a leader in the field of data-driven medicine, and I am excited to work with their team to further enhance patient outcomes for individuals of all backgrounds and from all communities.”RAIN Stock 12 Months Forecast. $1.33. (27.88% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Rain Therapeutics in the last 3 months. The average price target is $1.33 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 27.88% change from the last price of $1.04.